Measures of response in clinical trials of systemic sclerosis: The Combined Response Index for Systemic Sclerosis (CRISS) and outcome measures in pulmonary arterial hypertension related to systemic sclerosis (EPOSS)

Dinesh Khanna, Oliver Distler, Jerome Avouac, Frank Behrens, Philip J. Clements, Christopher Denton, Ivan Foeldvari, Edward Giannini, Doerte Huscher, Otylia Kowal-Bielecka, Daniel Lovell, Marco Matucci-Cerinic, Maureen Mayes, Peter A. Merkel, Peter Nash, Christian F. Opitz, David Pittrow, Lewis Rubin, James R. Seibold, Virginia SteenC. Vibeke Strand, Peter S. Tugwell, John Varga, Angela Zink, Daniel E. Furst

Research output: Contribution to journalArticlepeer-review

36 Scopus citations

Abstract

There have been steady efforts to develop a combined response index for systemic sclerosis (CRISS). A parallel and equally successful effort has been made by an Expert Panel on Outcome Measures in PAH related to Systemic Sclerosis (EPOSS) to measure effect in treatment of pulmonary arterial hypertension of systemic sclerosis (PAH-SSc). CRISS conducted a Delphi process combined with expert review to identify 11 candidate domains for inclusion in a core set of outcomes for SSc clinical trials: soluble biomarkers, cardiac, digital ulcers, gastrointestinal, global health, health related quality of life (HRQOL) and function, musculoskeletal, pulmonary, Raynaud's, renal, and skin. Tools within domains were also agreed upon. Concentrating on one aspect of disease, PAH, EPOSS also conducted a Delphi process and judged the following domains as the most appropriate for randomized controlled trials in PAH-SSc: lung vascular/pulmonary arterial pressure, cardiac function, exercise testing; severity of dyspnea, discontinuation of treatment; quality of life/activities of daily living; global state; and survival. Possible useful tools within each domain were also agreed on. Patient derived, physician derived, and objective measures of response will be included and combined with the idea that each reflects different aspects of PAH (EPOSS) and overall disease (CRISS) although this assumption may not prove true and can be separated if statistically and clinically valid to do so. In either case, prospective studies will require measurement of all domains, and tools are required and will be developed to define appropriate combined measures of response. CRISS and EPOSS are being developed through the OMERACT process. Through Delphi process and literature review significant progress has been made for both indices, and prospective data are being collected. The Journal of Rheumatology

Original languageEnglish (US)
Pages (from-to)2356-2361
Number of pages6
JournalJournal of Rheumatology
Volume36
Issue number10
DOIs
StatePublished - Oct 2009

Keywords

  • Clinical trials
  • Criss
  • Eposs
  • Omeract
  • Outcomes
  • Scleroderma

ASJC Scopus subject areas

  • Rheumatology
  • Immunology and Allergy
  • Immunology

Fingerprint Dive into the research topics of 'Measures of response in clinical trials of systemic sclerosis: The Combined Response Index for Systemic Sclerosis (CRISS) and outcome measures in pulmonary arterial hypertension related to systemic sclerosis (EPOSS)'. Together they form a unique fingerprint.

Cite this